Nino Mihatov1,2, Eric A Secemsky1, Dean J Kereiakes3, Gabriel Steg4, Patrick W Serruys5, Ply Chichareon6,7, Changyu Shen1, Robert W Yeh1. 1. Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. 2. Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3. The Christ Hospital Heart and Vascular Center, The Lindner Research Center, Cincinnati, Ohio, USA. 4. Université Paris-Diderot, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, INSERM U-1148, FACT (French Alliance for Cardiovascular Trials), Paris, France. 5. Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; National Heart and Lung Institute, Imperial College, London, UK. 6. Amsterdam UMC, University of Amsterdam, Heart Center; Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. 7. Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Abstract
BACKGROUND: The dual antiplatelet therapy (DAPT) score, one of the first prediction tools to attempt to uncouple bleeding and ischemic risk following percutaneous coronary intervention, can help guide antiplatelet duration after coronary intervention. Evaluating the generalizability of the score is important to understand its utility in clinical practice. METHODS: We conducted a systematic review and meta-analysis of studies that validated the DAPT score. A random effect meta-analysis was performed of ischemic and bleeding risk based on DAPT score. A secondary analysis assessed the risk of longer versus shorter P2Y12 inhibitor duration on ischemic and bleeding risk in randomized controlled trials of DAPT duration. RESULTS: We identified 10 patient cohorts involving 88,563 patients. Compared with a low DAPT score, a high DAPT score was associated with increased ischemic risk (RR: 1.62, 95% CI: 1.41-1.87) and reduced bleeding risk (RR: 0.80, 95% CI: 0.70-0.92). In three randomized trials of DAPT duration that contained information on the DAPT score, the relative risk of net adverse clinical events (combined ischemic and bleeding events) with longer duration of DAPT was 1.56 (95% CI: 0.77-3.19) for low DAPT score patients, and 0.86 (95% CI: 0.61-1.21) for high DAPT score patients (pinteraction = .14). CONCLUSIONS: In this large meta-analysis, the DAPT score consistently stratified bleeding and ischemic risk in opposing directions across several different study populations. More evaluation is needed to understand if the effect of longer DAPT duration on NACE is modified by the DAPT score in current practice.
BACKGROUND: The dual antiplatelet therapy (DAPT) score, one of the first prediction tools to attempt to uncouple bleeding and ischemic risk following percutaneous coronary intervention, can help guide antiplatelet duration after coronary intervention. Evaluating the generalizability of the score is important to understand its utility in clinical practice. METHODS: We conducted a systematic review and meta-analysis of studies that validated the DAPT score. A random effect meta-analysis was performed of ischemic and bleeding risk based on DAPT score. A secondary analysis assessed the risk of longer versus shorter P2Y12 inhibitor duration on ischemic and bleeding risk in randomized controlled trials of DAPT duration. RESULTS: We identified 10 patient cohorts involving 88,563 patients. Compared with a low DAPT score, a high DAPT score was associated with increased ischemic risk (RR: 1.62, 95% CI: 1.41-1.87) and reduced bleeding risk (RR: 0.80, 95% CI: 0.70-0.92). In three randomized trials of DAPT duration that contained information on the DAPT score, the relative risk of net adverse clinical events (combined ischemic and bleeding events) with longer duration of DAPT was 1.56 (95% CI: 0.77-3.19) for low DAPT score patients, and 0.86 (95% CI: 0.61-1.21) for high DAPT score patients (pinteraction = .14). CONCLUSIONS: In this large meta-analysis, the DAPT score consistently stratified bleeding and ischemic risk in opposing directions across several different study populations. More evaluation is needed to understand if the effect of longer DAPT duration on NACE is modified by the DAPT score in current practice.
Authors: Ply Chichareon; Rodrigo Modolo; Hideyuki Kawashima; Kuniaki Takahashi; Norihiro Kogame; Chun-Chin Chang; Mariusz Tomaniak; Masafumi Ono; Simon Walsh; Harry Suryapranata; James Cotton; Rene Koning; Ibrahim Akin; Neville Kukreja; Joanna Wykrzykowska; Jan J Piek; Scot Garg; Christian Hamm; Philippe Gabriel Steg; Peter Jüni; Pascal Vranckx; Marco Valgimigli; Stephan Windecker; Yoshinobu Onuma; Patrick W Serruys Journal: JACC Cardiovasc Interv Date: 2020-03-09 Impact factor: 11.195
Authors: E Boersma; K S Pieper; E W Steyerberg; R G Wilcox; W C Chang; K L Lee; K M Akkerhuis; R A Harrington; J W Deckers; P W Armstrong; A M Lincoff; R M Califf; E J Topol; M L Simoons Journal: Circulation Date: 2000-06-06 Impact factor: 29.690
Authors: Roxana Mehran; Stuart J Pocock; Eugenia Nikolsky; Tim Clayton; George D Dangas; Ajay J Kirtane; Helen Parise; Martin Fahy; Steven V Manoukian; Frederick Feit; Magnus E Ohman; Bernard Witzenbichler; Giulio Guagliumi; Alexandra J Lansky; Gregg W Stone Journal: J Am Coll Cardiol Date: 2010-06-08 Impact factor: 24.094
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: Edoardo Camenzind; William Wijns; Laura Mauri; Volkhard Kurowski; Keyur Parikh; Runlin Gao; Christoph Bode; John P Greenwood; Eric Boersma; Pascal Vranckx; Eugene McFadden; Patrick W Serruys; William W O'Neil; Brenda Jorissen; Frank Van Leeuwen; Ph Gabriel Steg Journal: Lancet Date: 2012-08-27 Impact factor: 79.321
Authors: Jonathan Ac Sterne; Miguel A Hernán; Barnaby C Reeves; Jelena Savović; Nancy D Berkman; Meera Viswanathan; David Henry; Douglas G Altman; Mohammed T Ansari; Isabelle Boutron; James R Carpenter; An-Wen Chan; Rachel Churchill; Jonathan J Deeks; Asbjørn Hróbjartsson; Jamie Kirkham; Peter Jüni; Yoon K Loke; Theresa D Pigott; Craig R Ramsay; Deborah Regidor; Hannah R Rothstein; Lakhbir Sandhu; Pasqualina L Santaguida; Holger J Schünemann; Beverly Shea; Ian Shrier; Peter Tugwell; Lucy Turner; Jeffrey C Valentine; Hugh Waddington; Elizabeth Waters; George A Wells; Penny F Whiting; Julian Pt Higgins Journal: BMJ Date: 2016-10-12
Authors: Elvin Kedhi; Enrico Fabris; Martin van der Ent; Pawel Buszman; Clemens von Birgelen; Vincent Roolvink; Alexander Zurakowski; Carl E Schotborgh; Jan C A Hoorntje; Christian Hasbø Eek; Stéphane Cook; Marco Togni; Martijn Meuwissen; Niels van Royen; Ria van Vliet; Hans Wedel; Ronak Delewi; Felix Zijlstra Journal: BMJ Date: 2018-10-02
Authors: Mohammad Alkhalil; Michał Kuzemczak; Alan Bell; Sol Stern; Michelle Welsford; Warren J Cantor; Shaun G Goodman Journal: CMAJ Date: 2022-02-14 Impact factor: 8.262
Authors: Mohammad Alkhalil; Michał Kuzemczak; Alan Bell; Sol Stern; Michelle Welsford; Warren J Cantor; Shaun G Goodman Journal: CMAJ Date: 2022-05-02 Impact factor: 16.859